Leptomeningeal disease is a serious complication of cancer in which tumor cells spread to the thin membranes surrounding the brain and spinal cord. It occurs in roughly 5% to 8% of breast cancer patients, up to 25% of lung cancer patients, and as many as 30% of those with melanoma. The condition goes by several names, including leptomeningeal carcinomatosis, leptomeningeal metastases, and sometimes “carcinomatous meningitis.”
Where It Happens in the Brain
Your brain and spinal cord are wrapped in three protective layers called the meninges. The outermost layer, the dura mater, is thick and tough. The two inner layers, the arachnoid mater and the pia mater, are much thinner and are collectively called the leptomeninges (from the Greek word “lepto,” meaning thin). Between these two inner layers flows cerebrospinal fluid (CSF), the clear liquid that cushions and nourishes the central nervous system.
In leptomeningeal disease, cancer cells infiltrate this fluid-filled space. Once there, they can travel freely along the surface of the brain and spinal cord, seeding new sites of disease far from the original tumor. This is what makes the condition so difficult to control: rather than forming a single tumor that can be targeted, cancer cells float and settle throughout the entire central nervous system.
Which Cancers Cause It
Almost any solid tumor can spread to the leptomeninges, but three cancers account for the vast majority of cases. Breast cancer is the most common source, followed by lung cancer (particularly small cell lung cancer) and melanoma. Blood cancers like leukemia and lymphoma can also involve the leptomeninges, a condition sometimes called leukemic or lymphomatous meningitis.
Leptomeningeal disease typically develops in people with advanced cancer that has already spread to other parts of the body. It tends to appear later in the disease course, though in some cases it can be the first sign that cancer has progressed.
Symptoms and How They Vary
Because cancer cells can settle anywhere along the brain and spinal cord, symptoms vary widely from person to person. Pain and seizures are the most common reasons people first seek medical attention. Headaches, often accompanied by nausea, vomiting, or lightheadedness, are also frequent early complaints.
Cranial nerve problems are the most common clinical finding, appearing in up to 94% of patients. The cranial nerves control functions like eye movement, facial sensation, swallowing, and hearing. When cancer cells damage these nerves, the effects can include double vision (the single most common cranial nerve symptom), facial numbness or weakness, difficulty swallowing, slurred speech, hearing loss, and vertigo. Multiple cranial nerves are usually affected rather than just one.
When the disease involves the spinal cord and its nerve roots, symptoms often mimic other conditions. Loss or asymmetry of reflexes occurs in about 70% of patients. Leg weakness, numbness, and tingling are common, and lumbar nerve root involvement can closely resemble a herniated disc. Some people develop bladder or bowel incontinence.
Cerebral involvement, where cancer affects the brain surface more broadly, can cause lethargy, confusion, memory problems, personality changes, and difficulty walking. Because so many different neurological symptoms can appear, and because they often develop gradually, leptomeningeal disease can be challenging to recognize early.
How It Is Diagnosed
Diagnosis relies on two main tools: MRI imaging and analysis of the cerebrospinal fluid.
Contrast-enhanced MRI can reveal characteristic patterns of abnormal enhancement along the leptomeninges. Radiologists look for bright signal in the subarachnoid space that appears after contrast dye is given, typically in nodular or linear shapes along the brain and spinal cord surface. MRI can also identify complications like hydrocephalus (fluid buildup in the brain).
The traditional gold standard for confirming the diagnosis is finding cancer cells in the cerebrospinal fluid, collected through a lumbar puncture (spinal tap). However, this test misses a significant number of cases. Sensitivity on the first spinal tap ranges from only 44% to 67%, meaning cancer cells go undetected in roughly a third to half of patients who actually have the disease. A second spinal tap raises detection to 84% to 91%, so repeat testing is often necessary when suspicion remains high.
Newer laboratory techniques that analyze cell-free DNA fragments shed by tumors into the spinal fluid have shown higher sensitivity than traditional cytology. These liquid biopsy approaches can detect genetic material from cancer cells even when the cells themselves are too scarce to find under a microscope.
Treatment Approaches
Treatment for leptomeningeal disease aims to control symptoms, slow the spread of cancer within the nervous system, and maintain quality of life. The main options include delivering chemotherapy directly into the spinal fluid, radiation therapy, and systemic drugs that can cross the blood-brain barrier.
Chemotherapy Into the Spinal Fluid
Because most standard chemotherapy drugs cannot cross from the bloodstream into the central nervous system in meaningful amounts, medication is often delivered directly into the cerebrospinal fluid. This is called intrathecal therapy. Methotrexate is one of the most commonly used drugs for this purpose.
To avoid repeated spinal taps, surgeons can implant a small device called an Ommaya reservoir beneath the scalp. It consists of a dome-shaped chamber connected to a thin tube that reaches into the brain’s fluid-filled ventricles. Once in place, clinicians can inject chemotherapy and withdraw CSF samples simply by inserting a needle through the skin into the reservoir. This makes ongoing treatment far more practical and comfortable.
Radiation Therapy
Radiation is typically directed at specific areas causing the most symptoms, such as spots where bulky tumor deposits are compressing nerves or blocking the flow of spinal fluid. It can provide relatively rapid relief of pain, weakness, or other focal problems.
Targeted Systemic Therapies
For certain cancer types with specific genetic mutations, newer targeted drugs have shown the ability to penetrate the central nervous system. In patients with EGFR-mutant lung cancer, for example, one targeted drug given at a higher-than-standard dose achieved response rates of 62% in the leptomeninges, with a median time before the disease progressed again of about 8.6 months. Other targeted agents have shown activity in ALK-positive lung cancer and HER2-positive breast cancer involving the leptomeninges, though the number of patients studied remains small. These advances represent a meaningful shift, because historically, systemic therapies were considered largely ineffective for disease inside the central nervous system.
Hydrocephalus as a Complication
One of the most urgent complications of leptomeningeal disease is hydrocephalus, a dangerous buildup of cerebrospinal fluid inside the brain. This happens when tumor cells block the normal pathways through which spinal fluid drains and recirculates. The resulting pressure increase causes worsening headaches, nausea, vision changes, and declining consciousness.
When hydrocephalus develops, a surgically placed shunt can redirect excess fluid from the brain’s ventricles to the abdominal cavity, rapidly relieving pressure and improving symptoms. There is no firm consensus on exactly which patients benefit most from this procedure, but evidence suggests that patients who still have reasonable functional ability before surgery tend to have better outcomes. For those who are already very debilitated, the risks of surgery may outweigh the benefits, though even some patients with poor functional status have experienced improved quality of life after shunt placement.
Prognosis and What to Expect
Leptomeningeal disease carries a difficult prognosis. Without treatment, survival is typically measured in weeks. With treatment, median survival extends to a few months for most solid tumor types, though this varies considerably depending on the type of cancer, how well it responds to therapy, and the person’s overall health at diagnosis.
Certain patients do notably better. Those with targeted therapy options, like EGFR-mutant lung cancer patients treated with newer agents, have shown median survival times reaching 11 to 13 months in clinical studies. Patients with blood cancers involving the leptomeninges also tend to respond better to treatment than those with solid tumors. How well someone is functioning at the time of diagnosis, measured by their ability to care for themselves and carry out daily activities, is one of the strongest predictors of how they will do with treatment.
The goals of treatment are honest: controlling symptoms, preserving neurological function for as long as possible, and maintaining quality of life. As newer targeted therapies and diagnostic tools continue to improve, outcomes for certain subgroups of patients have begun to shift in a more hopeful direction.